2Alvarez J A, Scully R E, Miller T L, et al. Long-term effects of treatments for childhood cancers[J]. Curr Opin Pediatr, 2007, 19(1) : 23 -31.
3Oeffinger K C, Mertens A C, Sklar C A, et al. Chronic health conditions in adult survivors of childhood cancer[J]. N Eng J Med, 2006, 355(15) :1572-1582.
4Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006 [J]. CA Cancer J Clin, 2006, 56(2):106-130.
5Armstrong G T, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Child- hood Cancer Survivor Study[J]. J Clin Oncol, 2009, 27(14): 2328-2338.
6Herman E H, Lipshultz S E, Rifai N, et al. Use of cardiac tro- ponin T levels as an indicator of doxorubicin-induced cardiotoxic- ity[J]. CancerRes, 1998, 58(2) :195-197.
7Lipshultz S E, Rifai N, Dalton V M, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia [J]. N Engl J Med, 2004, 351(2): 145-153.
8Mavinkurve-Groothuis A M, Groot-Loonen J, Bellersen L, et al. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines[J]. Pediatr Blood Cancer, 2009, 52(5):631-636.
9Billingham M E, Mason J W, Bristow M R, et al. Anthracy- dine eardiomyopathy monitored by morphologic changes[J]. Cancer Treat Rep, 1978, 62(6):865-872.
10Pouna P, Bonoron-Adele S, Gouverneur G, et al. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart~ comparison of new analogues versus doxorubicin [J]. Cancer Chemother Pharmacol, 1995, 35(3) :257-261.
